29 results about "Multivesicular liposomes" patented technology

Embodiments of the present disclosure relates to a new and improved large scale commercial manufacturing process of making bupivacaine multivesicular liposomes (MVLs). Batches of bupivacaine MVLs prepared by the new process have high yields, improved stabilities, and desired particle size distributions.

Embodiments of the present disclosure relates to a new and improved large scale commercial manufacturing process of making bupivacaine multivesicular liposomes (MVLs). Batches of bupivacaine MVLs prepared by the new process have high yields, improved stabilities, and desired particle size distributions.

Embodiments of the present disclosure relates to a new and improved large scale commercial manufacturing process of making bupivacaine multivesicular liposomes (MVLs). Batches of bupivacaine MVLs prepared by the new process have high yields, improved stabilities, and desired particle size distributions.

Embodiments of the present application relate to compositions bupivacaine multivesicular liposomes (MVLs) prepared by a commercial manufacturing process with large particle diameter span.

The invention relates to lidocaine multivesicular liposome as well as a preparation method and application thereof, belongs to the field of medicines, and solves at least one of the problems of higher toxicity, insufficient safety, short action time, limited clinical application range, higher cost and the like of the existing postoperative analgesic medicine. The lidocaine multi-vesicular liposome is prepared from lidocaine and a lipid, wherein the lidocaine and the lipid are added into the lidocaine multi-vesicular liposome; the lipid comprises amphiphilic lipid, negatively charged phospholipid, neutral lipid and cholesterol. The lidocaine multi-vesicular liposome prepared by the preparation method is high in safety, solves the problems of systemic toxicity, neurotoxicity, cardiotoxicity and the like of the existing postoperative analgesic drugs, has the characteristics of long-acting slow release, remarkable analgesic effect and wide clinical application range, and is suitable for clinical application. And a new solution is provided for effectively relieving postoperative pain.

The invention provides a recombinant protein IL-17A multivesicular liposome as well as a preparation method and application thereof, and belongs to the field of pharmaceutical preparations. The recombinant protein IL-17A multivesicular liposome is prepared from an oil phase, an inner water phase and an outer water phase, the oil phase consists of a lipid material and an organic solvent; the inner water phase consists of recombinant protein IL-17A and a sucrose water solution; and the outer water phase consists of a glucose aqueous solution and a lysine aqueous solution. The recombinant protein IL-17A multivesicular liposome is successfully prepared, the particle size of the recombinant protein IL-17A multivesicular liposome is small, the uniformity is good, the stability is good, the recombinant protein IL-17A can be stably and slowly released, and the slow release effect is achieved. A mouse depression model can be constructed by utilizing the recombinant protein IL-17A multivesicular liposome, and the recombinant protein IL-17A multivesicular liposome is used for related research of depression and has a good application prospect.

Embodiments of the present disclosure relates to commercial manufacturing process of making bupivacaine multivesicular liposomes with improved yield and desired particle size distribution.

In some embodiments, provided herein is a method of administering an adductor tube block in a patient wherein the method comprises: (a) selecting an entry point of an injection needle in a leg of the patient; (b) inserting an injection needle into the entry point of the patient's leg; (c) identifying a first nerve of the patient's leg; (d) administering normal saline and a pharmaceutical composition to the first nerve; (e) identifying a second nerve of the patient's leg; (f) administering normal saline and the pharmaceutical composition to the second nerve; wherein the first nerve and the second nerve are selected from the group consisting of a medial femoral muscular nerve (NVM) and an implicit nerve, and wherein the first nerve is not the second nerve; and wherein the pharmaceutical composition comprises a multivesicular liposome.

Embodiments of the present disclosure relates to a new and improved large scale commercial manufacturing process of making bupivacaine multivesicular liposomes (MVLs). Batches of bupivacaine MVLs prepared by the new process have high yields, improved stabilities, and desired particle size distributions.

The invention provides a high-stability blueberry anthocyanin polycystic liposome and a preparation method of the high-stability blueberry anthocyanin polycystic liposome. The preparation raw materials comprise 5 to 12 parts of a pH response type phospholipid derivative, 3 to 8 parts of mesoporous silica-polydopamine hybrid nanoparticles, 28 to 42 parts of egg yolk lecithin, 8 to 12 parts of cholesterol, 5 to 9 parts of glyceryl trioleate, 2 to 5 parts of vitamin E succinate, 10 to 18 parts of a citric acid-malic acid buffer solution, 45 to 85 parts of trehalose, 16 to 32 parts of a Tween 80-Arabic gum compound, 4 to 8 parts of chitosan quaternary ammonium salt and 5 to 13 parts of polyethylene glycol-2000. 160-280 parts of ultrapure water and 6-22 parts of blueberry anthocyanin. The blueberry anthocyanin polycystic liposome disclosed by the invention has high encapsulation efficiency, excellent photo-thermal stability and long-term storage stability.

The invention discloses a preparation method and application of a biological medicine, the biological medicine is prepared by compounding alizarin, carrageenan oligosaccharide, agaro-oligosaccharide and a croton vine ethanol extract and taking a multivesicular liposome as a carrier, and through compounding of effective components and matching of the carrier with a slow release effect, the biological medicine can effectively treat kidney bean rust fungi, and has a good application prospect. The composition can effectively kill fungi and stimulate crop resistance, has long-lasting pesticide effect, good pesticide stability, easily degradable components and no residual toxicity, and provides support for development of a novel medicament for preventing and treating the kidney bean rust disease.

Embodiments of the present application relate to batches of bupivacaine multivesicular liposomes (MVLs) prepared by a commercial manufacturing process using independently operating dual tangential flow filtration modules.

The present invention relates to an injectable pharmaceutical composition comprising bupivacaine or a pharmaceutically acceptable salt thereof. In particular, the present invention further relates to an aqueous multivesicular liposomal composition of bupivacaine or a pharmaceutically acceptable salt thereof, and a process of preparation thereof.

The invention provides bupivacaine multivesicular liposome, gel and composition as well as a preparation method and application of the bupivacaine multivesicular liposome and gel. The bupivacaine polycystic liposome disclosed by the invention is prepared from the following components: 8 to 20 mg / mL of phosphoric acid, 5 to 15 mg / mL of dierucyl phosphatidylcholine, 0.5 to 5 mg / mL of dipalmitoyl phosphatidyl glycerol, 0.5 to 5 mg / mL of tricaprylin, 2 to 10 mg / mL of cholesterol, 15 to 35 mg / mL of bupivacaine, 25 to 140 mg / mL of lysine, 55 to 400 mg / mL of osmotic pressure regulator and 15 to 20 mg / mL of sodium chloride. The gel containing the bupivacaine multivesicular liposome and the composition provided by the invention can improve the analgesic effect, prolong the analgesic time and play a slow-release analgesic role, and can be applied to the field of postoperative slow-release long-acting multimode analgesia, and the used materials are non-toxic and non-irritant, and have good biocompatibility and degradability.

Embodiments of the present disclosure relate to the use of bupivacaine multivesicular liposomes (MVLs) as stellate ganglion block (SGB) for treating or ameliorating various diseases and conditions, including but not limited to cardiac electrical storm or cardiac arrythmia / dysrhythmia following heart surgery.

The invention discloses treprostinil multivesicular liposome for treating pulmonary arterial hypertension. The multivesicular liposome is prepared from an inner water phase, an oil phase and an outer water phase through a double emulsification method, the treprostinil is dissolved in the inner water phase; the oil phase comprises soybean lecithin, cholesterol, glyceryl trioleate and electronegative lipid; the inner water phase and the outer water phase are body fluid isotonic solutions. The treprostinil multivesicular liposome disclosed by the invention has good stability and high encapsulation efficiency, obviously reduces burst release effect, shows obvious slow release characteristic, is beneficial to prolonging in-vivo drug half-life period, and can realize 48-hour treatment, reduce administration frequency, simplify administration method and improve patient compliance through simple subcutaneous injection. After the treprostinil multivesicular liposome is injected once, the inflammatory reaction of the injection part can be eliminated within 7 days, and the treprostinil multivesicular liposome has good safety.

The present disclosure relates to a new and improved large scale commercial manufacturing process of making bupivacaine multivesicular liposomes (MVLs) comprising DPEC, DPPG, cholesterol and tricaprylin. Batches of bupivacaine MVLs prepared by the new process have high yields, improved stability profiles, and desired particle size distributions.

Embodiments of the present disclosure relate to the use of bupivacaine multivesicular liposomes (MVLs) as stellate ganglion block (SGB) for treating or ameliorating various diseases and conditions, including but not limited to cardiac electrical storm or cardiac arrythmia / dysrhythmia following heart surgery.

The invention provides a preparation method of a multi-vesicular liposome based on carbon dot labeled protein, and aims to improve the biological stability and the treatment effect of a medicine. The preparation process comprises the steps of dissolving the mixed lipid, mixing and emulsifying the carbon quantum dots and the protein, preparing multiple emulsion and the like. The multivesicular liposome has a fluorescent label, is convenient for monitoring in-vivo drug distribution and release, and is beneficial to optimizing a drug administration scheme. The specific implementation mode comprises stability verification, encapsulation rate calculation, cytotoxicity and uptake testing and morphological observation.

Embodiments of the present disclosure relate to a new and improved large scale commercial manufacturing process of making bupivacaine multivesicular liposomes (MVLs). Batches of bupivacaine MVLs prepared by the new process have high yields, improved stabilities, and desired particle size distributions.

Embodiments of the present disclosure relate to a new and improved large scale commercial manufacturing process of making bupivacaine multivesicular liposomes (MVLs). Batches of bupivacaine MVLs prepared by the new process have high yields, improved stabilities, and desired particle size distributions.

Provided herein are methods of administration to the fibular and tibial nerves of a patient, wherein the methods comprise: (a) selecting an entry point of an injection needle at the leg of the patient; (b) inserting an injection needle into the entry point of the patient; (c) administering the saline and the pharmaceutical composition to the sciatic nerve of the patient through the injection needle; wherein the pharmaceutical composition comprises a multi-vesicular liposome, the multi-vesicular liposome comprises at least one amphiphilic lipid, at least one neutral lipid and bupivacaine phosphate, and the bupivacaine phosphate is encapsulated in the multi-vesicular liposome.

Embodiments of the present application relate to commercial manufacturing processes for making bupivacaine multivesicular liposomes (MVLs) using independently operating dual tangential flow filtration modules.

The application discloses an analysis method of a multivesicular liposome composition and belongs to the technical field of drug analysis. The analysis method is characterized by adopting a C8 chromatographic column, a buffer aqueous solution and an organic phase as a mobile phase, gradient elution, analysis and separation of composition components and hydrolysis products of the multivesicular liposome composition, and quantitative calculation of the composition components and the hydrolysis product content. The application is favorable for better monitoring of the quality of the multivesicular liposome composition product and provides a powerful guarantee for development of the multivesicular liposome composition.

The present application relates to the field of food health care technology, and particularly relates to mulberry leaf extract polycapsule liposome, a preparation method, health food and a blood sugar reducing application thereof; the mulberry leaf extract polycapsule liposome comprises mulberry leaf extract and blank polycapsule liposome; the mulberry leaf extract comprises mulberry leaf flavone and mulberry leaf alkaloid; the blank polycapsule liposome is composed of lipid bilayer, and comprises a plurality of aqueous chambers inside and is separated by the lipid bilayer between the aqueous chambers; wherein the mulberry leaf flavone is located between the lipid bilayers, and the mulberry leaf alkaloid is located inside the aqueous chambers. The mulberry leaf extract polycapsule liposome provided by the present application can simultaneously achieve embedding of the mulberry leaf flavone and the mulberry leaf alkaloid, thereby better achieving a blood sugar reducing effect.

The present disclosure relates to a new and improved large scale commercial manufacturing process of making bupivacaine multivesicular liposomes (MVLs) comprising DPEC, DPPG, cholesterol and tricapryl

Embodiments of the present disclosure relate to methods of using bupivacaine multivesicular liposomes (MVLs) as stellate ganglion block (SGB) for treating or ameliorating a sympathetic nervous system disorder associated with overactive or unbalanced sympathetic nervous system, including but not limited to, Raynaud's syndrome, post-mastectomy pain, reflex sympathetic dystrophy (RSD), phantom limb pain, hyperhidrosis, trigeminal neuralgia / facial pain, scleroderma, and long COVID.

The present disclosure relates to a new and improved large scale commercial manufacturing process of making bupivacaine multivesicular liposomes (MVLs) comprising DPEC, DPPG, cholesterol and tricaprylin. Batches of bupivacaine MVLs prepared by the new process have high yields, improved stability profiles, and desired particle size distributions.

The present application relates to the technical field of hydrogel and its preparation, and discloses a chitosan-based gradient hydrogel, a preparation method and application thereof, wherein thiolated chitosan and curcumin-loaded multivesicular liposomes are dissolved in an alpha-ketoglutaric acid aqueous solution, N-hydroxysuccinimidyl acrylate and hydroxyapatite are dissolved in another deionized water, and the two solutions are mixed, and the pH value of the system is adjusted to neutral to obtain a bone layer gel. According to the above gel preparation method, the hydroxyapatite is replaced by cartilage root to obtain a cartilage layer gel. The bone layer gel is placed at the bottom layer, and the cartilage layer gel is placed at the top layer, and a chitosan-based gradient hydrogel is prepared integrally. The chitosan-based bone-cartilage gradient hydrogel constructed by the present application can better simulate the bone-cartilage gradient structure and the bone-cartilage interface, the cartilage layer gel promotes chondrogenesis, the bone layer gel promotes osteogenesis, and the slow release of curcumin adjusts the inflammatory microenvironment to maintain the phenotype.